Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752371 | 0.85 | PDGFRB (0.46) | FPR2KITPDGFRBPDGFRAFYN | |
| SCHEMBL17752358 | 0.85 | SCN9A (0.37) | FPR2ABCB1KITSCN9A | |
| SCHEMBL17752376 | 0.77 | FPR2 (0.44) | FPR2SCN9AFYN | |
| SCHEMBL15031958 | 0.76 | KIT (0.46) | ABCB1KITERN1PDGFRBPDGFRA | |
| SCHEMBL12434759 | 0.75 | S1PR1 (0.37) | FPR2KITSCN9AERN1 | |
| SCHEMBL16290800 | 0.74 | ERN1 (0.36) | FPR2ABCB1SCN9AERN1ABCC1 | |
| SCHEMBL17752326 | 0.73 | LCK (0.41) | ERN1FYN | |
| SCHEMBL16290599 | 0.73 | KIT (0.35) | ABCB1KITSCN9AERN1ABCC1 | |
| SCHEMBL15031956 | 0.73 | HTR2A (0.40) | PDGFRB | |
| SCHEMBL16306439 | 0.73 | FYN (0.34) | FPR2ABCB1KITSCN9AERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9458152-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | FPR2 1884/4885ABCB1 230/4885KIT 1849/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | FPR2 2849/4885ABCB1 292/4885KIT 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.